Hayden E. Klein

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Researchers said longitudinal studies are critical to refine and optimize the management of metabolic dysfunction–associated steatotic liver disease (MASLD).

Merrill Stewart, MD, Ochsner Health, says insufficient funding from CMS for graduate medical education (GME) limits the ability to expand cardiology fellowships and contributes to the nationwide physician shortage.

High infection rates among younger adults suggest they either delay routine dental care and only seek treatment when conditions become severe, or face more barriers.

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, says Mansi Shah, MD.

Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and improve shared decision-making.

In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss in lean muscle.

Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple myeloma.

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

Merrill H. Stewart, MD, Ochsner Health, explains how his practice takes advantage of downtime during cardiologist appointments to educate patients.

Compared with tezepelumab, solrikitug demonstrated unique epitope binding and superior potency across several assays.

Data from 2019 to 2023 show 9.2% of adults with obesity reported cost-related medication adherence.

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these gains easier to maintain, explained Hamlet Gasoyan, PhD.

There was no association observed between lower income and increased fibrosis among New York City residents with metabolic dysfunction-associated steatohepatitis (MASH).

Patients who see a cardiologist at least once a year are about 24% less likely to die in the following year.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, BCOP, of Robert Wood Johnson University Hospital.

Merrill H. Stewart, MD, Ochsner Health, outlines the financial, logistical, and reimbursement barriers slowing the adoption of cardiac stress testing, but growing recognition of its long-term value could drive wider use.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP-1) receptor agonists, reducing their effectiveness for weight loss, explains Hamlet Gasoyan, PhD, Cleveland Clinic.

A global surge in rheumatoid arthritis with local hotspots highlights the need for targeted public health interventions.

The Global Liver Institute urges worldwide integration of liver health into diabetes and obesity care as steatotic liver disease surges.

Tocilizumab alone and in combination with methotrexate outperformed the latter drug in patients who did not adequately respond to conventional synthetic disease-modifying antirheumatic drugs.

Effective toxicity management in oncology requires pharmacists to document interventions clearly and collaborate closely with multidisciplinary teams, says David Awad, PharmD, BCOP.

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

The CDC’s Advisory Committee on Immunization Practices was expected to meet later in June to issue recommendations for use.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.